Last updated: June 18, 2026
Taiho v. Eugia (1:19-cv-02309): Litigation Summary, Docket Timeline, and Patent/Risk Analysis
Executive summary: Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd., 1:19-cv-02309 (D.N.J.) is a U.S. Hatch-Waxman patent-infringement action tied to a branded product in Taiho’s portfolio. The case posture, key filing dates, asserted patents, and outcome determinative events must be read directly from the court docket entries (CM/ECF) and the complaint, infringement contentions, and any Markman, claim-construction, dispositive-motion, and settlement/consent orders. Without the underlying docket documents and filings, a complete and accurate litigation summary cannot be produced.
What does Taiho Pharma v. Eugia Pharma Specialities (1:19-cv-02309) claim and what patents are asserted?
A litigation summary requires the complaint’s content. In Hatch-Waxman cases, the complaint typically identifies:
- The FDA application and Orange Book-listed patents at issue (often including method-of-use, composition, formulation, and/or manufacturing patents).
- The Hatch-Waxman paragraph(s) referenced by the ANDA (commonly Paragraph IV).
- The specific asserted patent numbers and the asserted infringement theories (literal infringement and/or doctrine of equivalents).
- The defendants’ product and how it is alleged to infringe.
Missing docket/pleadings constraint: The asserted patent list and claim theories cannot be stated accurately without the complaint and any amendments.
Which legal causes of action usually appear in 1:19-cv-02309 Hatch-Waxman complaints?
Typical elements in these suits include:
- 35 U.S.C. § 271(e)(2) and/or § 271(a) theories (pre-approval infringement and/or post-approval infringement).
- Declaratory judgment on non-infringement and invalidity defenses (often raised in answers or amended pleadings).
- Remedies seeking injunctions and damages or a standing claim for injunctive relief.
When was 1:19-cv-02309 filed and what is the procedural timeline?
A correct timeline must come from docket events such as:
- Complaint filing date.
- Service and answer deadlines.
- Rule 26(f) conference and scheduling order date.
- Claim construction deadlines (Markman).
- Opening and responsive claim construction briefs.
- Motions to dismiss, stay motions, summary judgment motions.
- Pretrial orders and trial dates (if the case proceeded).
- Any stipulations of dismissal without prejudice or with prejudice.
- Any consent judgments or settlement orders.
Missing docket constraint: A full, date-precise timeline cannot be compiled without the docket entry list and the filed orders.
Key deadline checkpoints that usually shape Hatch-Waxman case risk
In D.N.J. Hatch-Waxman practice, the most decision-relevant points often are:
- Whether a Markman occurs and how claim scope narrows.
- Whether the court grants dispositive motions on non-infringement or invalidity.
- Whether the parties file a settlement agreement leading to dismissal or an agreed launch restriction.
- Whether the court resolves forum-specific procedural motions affecting proof burdens.
How do courts in Hatch-Waxman treat patent scope and invalidity in cases like Taiho v. Eugia?
A litigation analysis must connect the case to standard adjudicatory frameworks:
- Claim construction drives infringement outcomes in narrow-claim formulation/method patents.
- Invalidity often hinges on:
- § 102 novelty (anticipation),
- § 103 obviousness,
- § 112 written description/enablement and indefiniteness,
- and sometimes § 101 subject matter issues for certain functional claim constructs (less common for classic chemical pharma claims, but still litigated).
Missing record constraint: Without the parties’ briefing and the court’s rulings, the analysis cannot be tied to what actually happened in this case.
What Markman issues typically matter for pharmaceutical formulation and method-of-use patents?
Courts commonly focus on:
- Whether a claim requires a specific compositional range and how “about” or functional language is interpreted.
- Whether method-of-use claims require patient-specific steps and measurable treatment endpoints.
- Whether manufacturing constraints are limitations (process patents) or irrelevant “results” language.
What happened in Taiho v. Eugia: dismissal, settlement, consent judgment, or final judgment?
A litigation summary must identify the ending procedural posture. The main endpoint categories are:
- Judgment after trial (rare in many Hatch-Waxman suits).
- Summary judgment (invalidity or non-infringement).
- Consent judgment (often settlement-driven).
- Stipulated dismissal (with or without prejudice).
- Case transfer or stay (for related proceedings).
Missing docket constraint: The case outcome cannot be reported accurately without the dismissal/termination docket entry and the associated order text.
How strong is the patent estate and what infringement/invalidity risks does it create for Eugia’s generic entry?
Risk depends on:
- Whether asserted patents are core composition/formulation patents or peripheral patents (e.g., narrow method-of-use).
- Whether the asserted claims survive validity challenges in the same district.
- Whether the generic product design-around exists (differences in salts, polymorphs, excipients, or dosage form).
- Whether the court’s claim construction would likely preclude infringement.
Missing record constraint: The strength analysis requires:
- asserted patent numbers,
- claim charts and technical comparisons,
- and any court rulings or settlement terms referencing design-arounds and launch timing.
What is the Orange Book status and how does it drive the litigation posture in 1:19-cv-02309?
Orange Book status usually links to:
- The FDA-listed patents for the relevant NDA/ANDA reference listed drug.
- Whether Eugia’s filing triggered a Paragraph IV notice.
- The timing of the 30-month stay (if applicable) and the resulting litigation schedule.
Missing product constraint: The underlying FDA linkage is not identifiable from the case caption alone in a way that supports an accurate Orange Book mapping.
Which patents typically appear in Orange Book litigation across Taiho-branded products?
Across Hatch-Waxman disputes, Orange Book estates commonly include:
- Composition-of-matter patents.
- Formulation patents (including specific excipient systems).
- Method-of-use patents for particular indications or dosing regimens.
What generic entry risks exist for Eugia after Taiho v. Eugia (1:19-cv-02309)?
Generic entry risk is driven by:
- Court outcomes on infringement/invalidity of the asserted patents.
- Remaining unasserted patents listed in the Orange Book for the same drug.
- Whether other suits involving the same FDA product and patent estate exist.
- Settlement-driven “carve-outs” that restrict marketing until a date.
Missing outcome constraint: Risk cannot be quantified without knowing whether the case ended via settlement, dismissal, or a merits ruling.
How does Taiho v. Eugia compare with other Taiho patent-infringement cases in D.N.J. or other districts?
A meaningful comparison requires:
- The asserted patent types.
- Whether courts found similar claim constructions.
- Whether settlements in other cases imposed similar launch dates.
Missing dataset constraint: Other case comparisons cannot be made reliably without the asserted-patent identity for this matter and a set of comparable cases.
Key Takeaways
- A complete litigation summary for Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd., 1:19-cv-02309 requires the complaint and docket orders that specify asserted patents, procedural milestones, and the case disposition.
- With only the case caption and docket number, the litigation record cannot be converted into a date- and patent-accurate analysis.
FAQs
- What is the typical scope of infringement allegations in D.N.J. Hatch-Waxman cases like 1:19-cv-02309?
- How do claim constructions for method-of-use patents affect generic launch timing?
- What settlements commonly end Taiho-style patent cases, and what launch terms usually appear in consent judgments?
- How does the 30-month stay interact with later stipulations or dismissals in Hatch-Waxman litigation?
- What Orange Book patent categories most often drive litigation risk: composition, formulation, or method-of-use?
References
- United States District Court for the District of New Jersey. Case 1:19-cv-02309, Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd. (CM/ECF docket and filed documents).
